CASI
CASI Pharmaceuticals Inc
Price Chart
No historical data available
Latest Quote
$0.21
Current Price| Open | $0.34 |
| Day High | $0.37 |
| Day Low | $0.21 |
| Volume | 6,830,123 |
Stock Information
| Shares Outstanding | 20.55M |
| Total Debt | $18.86M |
| Cash Equivalents | $4.68M |
| Revenue | $26.85M |
| Net Income | $-49.38M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $4.26M |
| EPS (TTM) | $-3.02 |
| Exchange | NGM |
Recent Price History
No history data available. Data will be fetched automatically.
About CASI Pharmaceuticals Inc
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The company's hematology/oncology assets in pipeline include CNCT19, an autologous CD19 CAR-T investigative product; BI-1206, an novel anti-Fc?RIIB antibody for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. It has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.
đ° Latest News
Is Alkermes (ALKS) Outperforming Other Medical Stocks This Year?
Zacks âĸ 2026-02-02T14:40:03Z
Are Medical Stocks Lagging Alkermes (ALKS) This Year?
Zacks âĸ 2026-01-15T14:40:02Z
CASI Pharmaceuticals Second Quarter 2025 Earnings: Misses Expectations
Simply Wall St. âĸ 2025-08-31T13:29:10Z
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates
Zacks âĸ 2025-08-14T13:15:02Z
Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates
Zacks âĸ 2025-08-12T22:25:01Z
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates
Zacks âĸ 2025-08-07T21:55:02Z
Bioventus (BVS) Misses Q2 Earnings and Revenue Estimates
Zacks âĸ 2025-08-06T12:55:01Z
Indivior PLC (INDV) Tops Q2 Earnings and Revenue Estimates
Zacks âĸ 2025-07-31T12:15:03Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $17,391,000 | $13,827,000 | $15,827,000 | $12,557,000 |
| Cost Of Revenue | $17,391,000 | $13,827,000 | $15,827,000 | $12,557,000 |
| Total Revenue | $28,537,000 | $33,879,000 | $43,107,000 | $30,168,000 |
| Operating Revenue | $28,537,000 | $33,879,000 | $43,047,000 | $30,020,000 |
| Expenses | ||||
| Interest Expense | $871,000 | $15,000 | $62,000 | - |
| Total Expenses | $67,749,000 | $59,159,000 | $69,598,000 | $65,385,000 |
| Other Income Expense | $1,475,000 | $-1,626,000 | $-11,067,000 | $-946,000 |
| Other Non Operating Income Expenses | $188,000 | $764,000 | $44,000 | $558,000 |
| Net Non Operating Interest Income Expense | $-332,000 | $614,000 | $127,000 | $321,000 |
| Interest Expense Non Operating | $871,000 | $15,000 | $62,000 | - |
| Operating Expense | $50,358,000 | $45,332,000 | $53,771,000 | $52,828,000 |
| Other Operating Expenses | $-2,000 | $-6,366,000 | - | - |
| Selling And Marketing Expense | $17,866,000 | $16,450,000 | $14,326,000 | $14,705,000 |
| General And Administrative Expense | $23,577,000 | $25,387,000 | $23,449,000 | $23,701,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-39,258,000 | $-26,938,000 | $-41,014,000 | $-36,654,000 |
| Net Interest Income | $-332,000 | $614,000 | $127,000 | $321,000 |
| Interest Income | $539,000 | $629,000 | $189,000 | $321,000 |
| Normalized Income | $-40,545,000 | $-24,555,363 | $-28,687,000 | $-35,150,000 |
| Net Income From Continuing And Discontinued Operation | $-39,258,000 | $-26,938,000 | $-41,014,000 | $-36,654,000 |
| Total Operating Income As Reported | $-39,621,000 | $-25,080,000 | $-34,032,000 | $-41,516,000 |
| Net Income Common Stockholders | $-39,258,000 | $-26,960,000 | $-41,014,000 | $-36,654,000 |
| Net Income | $-39,258,000 | $-26,938,000 | $-41,014,000 | $-36,654,000 |
| Net Income Including Noncontrolling Interests | $-39,258,000 | $-26,259,000 | $-40,257,000 | $-35,842,000 |
| Net Income Continuous Operations | $-39,258,000 | $-26,259,000 | $-40,257,000 | $-35,842,000 |
| Earnings From Equity Interest Net Of Tax | $-1,189,000 | $-48,000 | $-846,000 | $0 |
| Pretax Income | $-38,069,000 | $-26,292,000 | $-37,431,000 | $-35,842,000 |
| Special Income Charges | $-217,000 | $-2,009,000 | $-10,782,000 | $-7,485,000 |
| Earnings From Equity Interest | $0 | $0 | $5,325,000 | $0 |
| Interest Income Non Operating | $539,000 | $629,000 | $189,000 | $321,000 |
| Operating Income | $-39,212,000 | $-25,280,000 | $-26,491,000 | $-35,217,000 |
| Gross Profit | $11,146,000 | $20,052,000 | $27,280,000 | $17,611,000 |
| Per Share | ||||
| Diluted EPS | $-2.56 | $-2.02 | $-3.01 | $-2.69 |
| Basic EPS | $-2.56 | $-2.02 | $-3.01 | $-2.69 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $-7,363 | $-4,109,000 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-36,154,000 | $-20,146,000 | $-18,511,000 | $-31,898,000 |
| Total Unusual Items | $1,287,000 | $-2,390,000 | $-16,436,000 | $-1,504,000 |
| Total Unusual Items Excluding Goodwill | $1,287,000 | $-2,390,000 | $-16,436,000 | $-1,504,000 |
| Reconciled Depreciation | $2,331,000 | $3,741,000 | $2,422,000 | $1,815,000 |
| EBITDA (Bullshit earnings) | $-34,867,000 | $-22,536,000 | $-34,947,000 | $-33,402,000 |
| EBIT | $-37,198,000 | $-26,277,000 | $-37,369,000 | $-35,217,000 |
| Diluted Average Shares | $15,340,277 | $13,360,185 | $13,647,455 | $13,610,441 |
| Basic Average Shares | $15,340,277 | $13,360,185 | $13,647,455 | $13,610,441 |
| Diluted NI Availto Com Stockholders | $-39,258,000 | $-26,960,000 | $-41,014,000 | $-36,654,000 |
| Minority Interests | $0 | $-679,000 | $-757,000 | $-812,000 |
| Tax Provision | $0 | $-81,000 | $1,980,000 | $0 |
| Gain On Sale Of Ppe | $479,000 | $0 | $-2,058,000 | $-65,000 |
| Write Off | $0 | $2,009,000 | $0 | $865,000 |
| Impairment Of Capital Assets | $696,000 | $0 | $8,724,000 | $0 |
| Gain On Sale Of Security | $1,504,000 | $-381,000 | $-5,654,000 | $5,981,000 |
| Research And Development | $8,917,000 | $9,861,000 | $15,996,000 | $14,422,000 |
| Selling General And Administration | $41,443,000 | $41,837,000 | $37,775,000 | $38,406,000 |
| Other Gand A | $23,577,000 | $25,387,000 | $23,449,000 | $23,701,000 |
| Preferred Stock Dividends | - | $22,000 | - | - |
| Other Special Charges | - | - | - | $6,555,000 |
| Restructuring And Mergern Acquisition | - | - | - | $6,555,000 |
Fetched: 2026-02-24
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $1,613,000 | $22,326,000 | $43,511,000 | $72,299,000 |
| Total Assets | $53,674,000 | $75,268,000 | $96,234,000 | $138,298,000 |
| Total Non Current Assets | $13,901,000 | $15,924,000 | $22,811,000 | $76,328,000 |
| Other Non Current Assets | $587,000 | $766,000 | $1,056,000 | $2,178,000 |
| Investmentin Financial Assets | $1,716,000 | $1,681,000 | $3,065,000 | $0 |
| Goodwill And Other Intangible Assets | $238,000 | $1,839,000 | $1,063,000 | $12,203,000 |
| Other Intangible Assets | $238,000 | $1,839,000 | $1,063,000 | $12,203,000 |
| Current Assets | $39,576,000 | $59,344,000 | $73,423,000 | $61,970,000 |
| Other Current Assets | $2,888,000 | $2,560,000 | $2,975,000 | $1,688,000 |
| Inventory | $5,252,000 | $15,877,000 | $6,138,000 | $1,907,000 |
| Receivables | $15,345,000 | $10,138,000 | $12,973,000 | $9,803,000 |
| Accounts Receivable | $15,345,000 | $9,551,000 | $12,973,000 | $9,803,000 |
| Cash Cash Equivalents And Short Term Investments | $16,091,000 | $30,769,000 | $51,337,000 | $48,572,000 |
| Cash And Cash Equivalents | $13,468,000 | $17,083,000 | $47,112,000 | $38,704,000 |
| Financial Assets | - | $5,000 | - | - |
| Allowance For Doubtful Accounts Receivable | - | - | $0 | $0 |
| Gross Accounts Receivable | - | - | $12,973,000 | $9,803,000 |
| Prepaid Assets | - | - | - | $1,688,000 |
| Debt | ||||
| Net Debt | $4,917,000 | $1,812,000 | - | - |
| Total Debt | $22,141,000 | $21,239,000 | $1,344,000 | $2,166,000 |
| Long Term Debt And Capital Lease Obligation | $2,535,000 | $20,511,000 | $476,000 | $1,105,000 |
| Current Debt And Capital Lease Obligation | $19,606,000 | $728,000 | $868,000 | $1,061,000 |
| Current Debt | $18,385,000 | - | - | - |
| Other Current Borrowings | $18,385,000 | - | - | - |
| Long Term Debt | - | $18,895,000 | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $51,823,000 | $51,103,000 | $29,302,000 | $30,339,000 |
| Total Non Current Liabilities Net Minority Interest | $15,371,000 | $34,377,000 | $12,297,000 | $17,153,000 |
| Other Non Current Liabilities | $11,821,000 | $11,821,000 | $11,821,000 | $13,220,000 |
| Tradeand Other Payables Non Current | $1,015,000 | $2,045,000 | $0 | - |
| Current Liabilities | $36,452,000 | $16,726,000 | $17,005,000 | $13,186,000 |
| Current Deferred Liabilities | $2,474,000 | $2,543,000 | $2,617,000 | - |
| Payables And Accrued Expenses | $14,372,000 | $13,455,000 | $13,520,000 | $11,606,000 |
| Payables | $13,038,000 | $12,337,000 | $12,872,000 | $11,546,000 |
| Other Payable | $8,466,000 | $7,146,000 | $7,533,000 | $8,671,000 |
| Dividends Payable | $1,849,000 | $753,000 | $0 | - |
| Accounts Payable | $2,723,000 | $4,438,000 | $3,289,000 | $2,223,000 |
| Total Tax Payable | - | $481,000 | $2,050,000 | $652,000 |
| Income Tax Payable | - | $0 | $1,900,000 | $0 |
| Non Current Deferred Liabilities | - | - | $0 | $2,828,000 |
| Other Current Liabilities | - | - | $648,000 | $519,000 |
| Equity | ||||
| Common Stock Equity | $1,851,000 | $24,165,000 | $44,574,000 | $84,502,000 |
| Total Equity Gross Minority Interest | $1,851,000 | $24,165,000 | $66,932,000 | $107,959,000 |
| Stockholders Equity | $1,851,000 | $24,165,000 | $44,574,000 | $84,502,000 |
| Gains Losses Not Affecting Retained Earnings | $-1,774,000 | $-1,200,000 | $-703,000 | $1,954,000 |
| Other Equity Adjustments | $-1,774,000 | $-1,200,000 | $-703,000 | $1,954,000 |
| Retained Earnings | $-700,075,000 | $-660,817,000 | $-637,160,000 | $-605,643,000 |
| Preferred Securities Outside Stock Equity | - | - | - | $23,457,000 |
| Other | ||||
| Treasury Shares Number | $411,952 | $411,952 | $275,834 | $7,954 |
| Ordinary Shares Number | $15,492,581 | $13,378,175 | $13,457,625 | $13,979,748 |
| Share Issued | $15,904,533 | $13,790,127 | $13,733,459 | $13,987,702 |
| Tangible Book Value | $1,613,000 | $22,326,000 | $43,511,000 | $72,299,000 |
| Invested Capital | $20,236,000 | $43,060,000 | $44,574,000 | $84,502,000 |
| Working Capital | $3,124,000 | $42,618,000 | $56,418,000 | $48,784,000 |
| Capital Lease Obligations | $3,756,000 | $2,344,000 | $1,344,000 | $2,166,000 |
| Total Capitalization | $1,851,000 | $43,060,000 | $44,574,000 | $84,502,000 |
| Treasury Stock | $9,604,000 | $9,604,000 | $9,330,000 | $8,034,000 |
| Additional Paid In Capital | $713,302,000 | $695,785,000 | $691,766,000 | $696,224,000 |
| Capital Stock | $2,000 | $1,000 | $1,000 | $1,000 |
| Common Stock | $2,000 | $1,000 | $1,000 | $1,000 |
| Long Term Capital Lease Obligation | $2,535,000 | $1,616,000 | $476,000 | $1,105,000 |
| Current Deferred Revenue | $2,474,000 | $2,543,000 | $2,617,000 | - |
| Current Capital Lease Obligation | $1,221,000 | $728,000 | $868,000 | $1,061,000 |
| Current Accrued Expenses | $1,334,000 | $1,118,000 | $648,000 | $60,000 |
| Investments And Advances | $1,716,000 | $1,681,000 | $7,463,000 | $40,128,000 |
| Available For Sale Securities | $1,716,000 | $1,681,000 | $3,065,000 | - |
| Net PPE | $11,360,000 | $11,633,000 | $13,229,000 | $21,819,000 |
| Accumulated Depreciation | $-5,707,000 | $-4,651,000 | $-2,299,000 | $-2,244,000 |
| Gross PPE | $17,067,000 | $16,284,000 | $15,528,000 | $24,063,000 |
| Leases | $6,995,000 | $7,190,000 | $7,161,000 | $1,133,000 |
| Construction In Progress | $0 | $23,000 | $5,728,000 | $12,095,000 |
| Other Properties | $3,492,000 | $2,392,000 | $1,398,000 | $9,107,000 |
| Machinery Furniture Equipment | $6,580,000 | $6,679,000 | $1,241,000 | $1,728,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $5,252,000 | $15,877,000 | $6,138,000 | $1,907,000 |
| Duefrom Related Parties Current | $0 | $587,000 | $0 | - |
| Other Short Term Investments | $2,623,000 | $13,686,000 | $4,225,000 | $9,868,000 |
| Minority Interest | - | $0 | $22,358,000 | $23,457,000 |
| Non Current Deferred Revenue | - | - | $0 | $2,828,000 |
| Other Investments | - | - | $4,398,000 | $40,128,000 |
| Preferred Stock | - | - | - | $0 |
| Line Of Credit | - | - | - | $0 |
Fetched: 2026-02-24
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-29,464,000 | $-22,208,000 | $-26,700,000 | $-42,342,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-29,224,000 | $-19,967,000 | $-21,088,000 | $-26,842,000 |
| Cash Flow From Continuing Operating Activities | $-29,224,000 | $-19,967,000 | $-21,088,000 | $-26,842,000 |
| Operating Gains Losses | $710,000 | $-426,000 | $-2,421,000 | $-407,000 |
| Investing Activities | ||||
| Capital Expenditure | $-240,000 | $-2,241,000 | $-5,612,000 | $-15,500,000 |
| Investing Cash Flow | $11,244,000 | $-9,673,000 | $31,159,000 | $-20,691,000 |
| Cash Flow From Continuing Investing Activities | $11,244,000 | $-9,673,000 | $31,159,000 | $-20,691,000 |
| Net Other Investing Changes | - | $1,000,000 | $6,436,000 | $-5,201,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $0 | $-278,000 | $-3,267,000 | $0 |
| Issuance Of Capital Stock | $15,000,000 | $0 | $0 | $32,500,000 |
| Financing Cash Flow | $15,434,000 | $-907,000 | $-3,267,000 | $29,642,000 |
| Cash Flow From Continuing Financing Activities | $15,434,000 | $-907,000 | $-3,267,000 | $29,642,000 |
| Net Other Financing Charges | $-1,678,000 | $-738,000 | - | $-2,019,000 |
| Net Common Stock Issuance | $15,000,000 | $-278,000 | $-3,267,000 | $32,500,000 |
| Common Stock Issuance | $15,000,000 | $0 | $0 | $32,500,000 |
| Other | ||||
| Repayment Of Debt | $0 | $0 | $-4,001,000 | $-1,548,000 |
| Issuance Of Debt | $0 | $0 | $4,001,000 | $709,000 |
| Interest Paid Supplemental Data | $0 | $0 | $62,000 | $42,000 |
| Income Tax Paid Supplemental Data | $0 | $1,807,000 | $0 | $0 |
| End Cash Position | $13,468,000 | $17,083,000 | $47,112,000 | $38,704,000 |
| Beginning Cash Position | $17,083,000 | $47,112,000 | $38,704,000 | $57,064,000 |
| Effect Of Exchange Rate Changes | $-1,069,000 | $518,000 | $1,604,000 | $-469,000 |
| Changes In Cash | $-2,546,000 | $-30,547,000 | $6,804,000 | $-17,891,000 |
| Proceeds From Stock Option Exercised | $2,112,000 | $109,000 | $0 | $0 |
| Common Stock Payments | $0 | $-278,000 | $-3,267,000 | $0 |
| Net Issuance Payments Of Debt | $0 | $0 | $0 | $-839,000 |
| Net Short Term Debt Issuance | $0 | $0 | $0 | $-839,000 |
| Short Term Debt Payments | $0 | $0 | $-4,001,000 | $-1,548,000 |
| Short Term Debt Issuance | $0 | $0 | $4,001,000 | $709,000 |
| Net Investment Purchase And Sale | $12,354,000 | $-8,432,000 | $-796,000 | $0 |
| Sale Of Investment | $13,761,000 | $43,322,000 | $3,731,000 | $0 |
| Purchase Of Investment | $-1,407,000 | $-51,754,000 | $-4,527,000 | $0 |
| Net Business Purchase And Sale | $-1,370,000 | $0 | $30,993,000 | $0 |
| Sale Of Business | $0 | $0 | $33,891,000 | $0 |
| Purchase Of Business | $-1,370,000 | $0 | $-2,898,000 | - |
| Net Intangibles Purchase And Sale | $483,000 | $-2,037,000 | $0 | $-6,555,000 |
| Sale Of Intangibles | $500,000 | $0 | $0 | $0 |
| Purchase Of Intangibles | $-17,000 | $-2,037,000 | $0 | $-6,555,000 |
| Net PPE Purchase And Sale | $-223,000 | $-204,000 | $-5,474,000 | $-8,935,000 |
| Sale Of PPE | $0 | $0 | $138,000 | $10,000 |
| Purchase Of PPE | $-223,000 | $-204,000 | $-5,612,000 | $-8,945,000 |
| Change In Working Capital | $771,000 | $-7,818,000 | $-6,650,000 | $-3,218,000 |
| Change In Payables And Accrued Expense | $-169,000 | $-1,615,000 | $2,134,000 | $3,794,000 |
| Change In Accrued Expense | $1,546,000 | $-876,000 | $-912,000 | $2,303,000 |
| Change In Payable | $-1,715,000 | $-739,000 | $3,046,000 | $1,491,000 |
| Change In Account Payable | $-1,715,000 | $1,149,000 | $1,066,000 | $1,491,000 |
| Change In Tax Payable | $0 | $-1,888,000 | $1,980,000 | $0 |
| Change In Income Tax Payable | $0 | $-1,888,000 | $1,980,000 | $0 |
| Change In Prepaid Assets | $319,000 | $701,000 | $-1,383,000 | $-1,303,000 |
| Change In Inventory | $5,828,000 | $-9,739,000 | $-4,231,000 | $-551,000 |
| Change In Receivables | $-5,207,000 | $2,835,000 | $-3,170,000 | $-5,158,000 |
| Changes In Account Receivables | $-5,794,000 | $3,422,000 | $-3,170,000 | $-5,158,000 |
| Stock Based Compensation | $1,306,000 | $7,217,000 | $7,010,000 | $7,770,000 |
| Unrealized Gain Loss On Investment Securities | $-1,696,000 | $581,000 | $8,895,000 | $-5,660,000 |
| Asset Impairment Charge | $6,612,000 | $2,997,000 | $9,913,000 | $2,145,000 |
| Depreciation Amortization Depletion | $2,331,000 | $3,741,000 | $2,422,000 | $1,815,000 |
| Depreciation And Amortization | $2,331,000 | $3,741,000 | $2,422,000 | $1,815,000 |
| Amortization Cash Flow | $1,061,000 | $1,287,000 | $1,210,000 | $1,347,000 |
| Amortization Of Intangibles | $1,061,000 | $1,287,000 | $1,210,000 | $1,347,000 |
| Depreciation | $1,270,000 | $2,454,000 | $1,212,000 | $468,000 |
| Earnings Losses From Equity Investments | $1,189,000 | $48,000 | $846,000 | $0 |
| Gain Loss On Sale Of PPE | $-479,000 | $0 | $2,058,000 | $65,000 |
| Net Income From Continuing Operations | $-39,258,000 | $-26,259,000 | $-40,257,000 | $-35,842,000 |
| Net Long Term Debt Issuance | - | - | $0 | $-1,548,000 |
| Long Term Debt Payments | - | - | $-4,001,000 | $-1,548,000 |
| Long Term Debt Issuance | - | - | $4,001,000 | $0 |
| Other Non Cash Items | - | - | $1,189,000 | $6,555,000 |
| Gain Loss On Investment Securities | - | - | $-5,325,000 | - |
| Change In Other Working Capital | - | - | - | $-51,000 |
Fetched: 2026-02-24